Teladoc Health spent the past year juggling a Walmart virtual care rollout, an expanding AI toolset like SoloVitals and SoloScribe, and a sharp reset in BetterHelp's cash-pay demand that even drew securities law firms into the story. For Teladoc Health shareholders, the return over the past year was 23.5%, including dividends. If you were deciding whether to buy on 5 November 2025, what exactly would you have needed to believe about chronic care, BetterHelp and legal risk to hold through all that?
A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.
Teladoc Health is not the only name tied to this theme. Zero in on 34 healthcare AI stocks and compare how each one is priced.
The Two Stories Teladoc Health Investors Were Arguing About
The shares cost US$8.06 at the start of the period, and Teladoc Health sat between two very different but credible stories about its future.
On the optimistic side, the Fair Value of US$9.13 rested on digital chronic care and international rollouts, as well as a belief that shifting toward pay-per-visit and AI-driven automation could eventually support higher net margins despite BetterHelp growing through lower-margin insurance revenue.
The more cautious case put Fair Value at US$7 and leaned on the idea that rising global data rules, reimbursement uncertainty, and pressure on BetterHelp's unit economics could keep revenue growth around 0.6% in decline.
What The Evidence Did To The Teladoc Health Argument
Teladoc Health launched Teladoc One and continued rolling out AI tools such as SoloVitals and SoloScribe, which supported the optimistic chronic care and international story. At the same time, BetterHelp revenue fell 9% year on year in Q1 2026 and Teladoc later cut 2026 revenue guidance, while net income remained a loss even as net margin improved to -4.5%. The evidence cut both ways.
The period turned on whether better chronic care tools and insurance partnerships could offset weaker cash pay mental health demand. For other stocks with similar questions, it may be helpful to focus on segment-level revenue trends, reported net margin direction, and any guidance changes that confirm or undercut each side of the story reflected in the current price.
What Teladoc Health's Price Seems To Assume Now
Teladoc Health now trades at US$9.41, after a 23.5% gain over the past year, and the selected Narrative's Fair Value sits below the current price.
The Narrative focuses on whether AI tools, Teladoc One and BetterHelp's insurance mix can still lift margins. A buyer today effectively backs that execution, so how does the selected Narrative's concern about slower revenue and segment mix weigh on that assumption?
"Key Takeaways: Bearish analysts expect Teladoc Health to keep facing rising compliance burdens, operational complexity and reimbursement pressure that limit the benefit of cost savings and weigh on long-term profitability. The main thing that has to go right is that Teladoc Health converts its AI-enabled, integrated care model and BetterHelp insurance shift into sustainable margin expansion while managing lower cash-pay growth and regulatory scrutiny."
That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for
Looking Past Teladoc's Front Door
Teladoc keeps your attention on virtual visits and digital care programs. Just outside that view, another business handles the hidden plumbing beneath all that traffic.
Every remote consult, chronic care check in, and AI tool needs serious computing power and nonstop data movement. That workload keeps rising as healthcare software grows more intricate.
One infrastructure provider builds hardware and software that move, connect, and secure this flow. It helps customers run private clouds, manage data centers, and keep applications talking.
If healthcare leans further into richer digital tools, this behind the scenes role could become more central. The open question is how much value eventually flows to the pipes.
One Narrative has put that dependency into a written case. → See the AI infrastructure company one Narrative values 123% above its price
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TDOC .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
